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Background: Reporting of adverse drug reactions (ADRs) has traditionally been the sole province of healthcare
professionals. In the European Union, more countries have allowed consumers to report ADRs directly to the
regulatory agencies. The aim of this study was to characterize ADRs reported by European consumer for nervous
system medications.
Methods: ADRs reported by consumers for nervous system medications (ATC group N) from 2007 to 2011 and
located in the European ADR database, EudraVigilance, were analysed. Data were categorized with respect to age
and sex, category and seriousness of reported ADRs and medications. The unit of analysis was one ADR.
Results: We located 4766 ADRs reported for nervous system medications, and one half of these were serious
including 19 deaths. Less than 5% of ADRs were reported in children. Totally, 58% of ADRs were reported for
women, 42% for men. The majority of reported ADRs were of the types “nervous system disorders” (18% of total
ADRs) followed by “psychiatric disorders” (18% of total ADRs) and “general disorders” (15% of total ADRs) which also
were the system organ classes in which the majority of serious ADRs were found. ADR reports encompassed
medicines from the therapeutic groups: antiepileptics (ATC group N03) (36% of total ADRs), parasympathomimetics
(ATC group N07) (22% of total ADRs) and antidepressants ATC group N06A (9% of total ADRs). Antiepileptics were
the therapeutic group with the highest share of serious ADRs (60%) followed by antidepressants (15%). Many
serious ADRs were reported for pregabalin and varenicline.
Conclusions: The majority of ADRs from nervous system mediations reported by consumers that were identified
from the EudraVigilance database were serious. The value of consumer reports in pharmacovigilance still remains
unclarified.
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Reporting of adverse drug reactions (ADRs) to national da-
tabases has traditionally been the sole province of health
care professionals [1]. In order to strengthen the systems
in some countries, consumers have also been allowed
to report ADRs directly to the regulatory agencies [2].
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distribution, and reproduction in any mediumtheir experience with medicines and may therefore consti-
tute a valuable information source [1,2]. The weakness of
consumer ADR reports is the lack of medical confirmation,
which might impede the interpretation of ADR causation
[2]. Only few studies have analysed consumer reports
submitted to ADR databases, but over the last years
studies analysing ADRs reported to national pharma-
covigilance databases have been published [3,4]. Medawar
and Herxheimer investigated ADR reports on the risk of
dependence and suicidal behaviour from paroxetine from
UK consumers and healthcare professionals, respectively
[5]. In 2011, McLernon et al. published a study investigat-
ing the characteristics of consumer ADRs reported in UKCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for consumers to ADR report directly to the non-profit
organization KILEN since 1978 [2], and research con-
ducted on these data has been published in several papers
and reports [7-10]. Experience with consumer reporting
(2004 to 2007) in the Netherlands was recently published
showing differences in the categories of seriousness
and outcome of the reported ADRs between patients
and healthcare professionals [11]. A study from Denmark
analysing differences in ADR reporting patterns between
consumers and healthcare professionals (2004 to 2006)
showed that patients were more likely to report ADRs
from nervous and psychiatric medications, that patients’
share of reports on serious ADRs was comparable to that
of physicians, and that patients provided new and un-
known information about ADRs [12]. Analysis of con-
sumer reports of suspected ADRs submitted voluntarily to
the website of a Danish consumer magazine showed that
consumers reported ADRs for nervous systems medica-
tions and that patients report rather unspecific symptoms,
as they use lay terms to describe reactions [13]. Patients
also reported several ADRs, which prescribers may not
consider serious but may be troublesome to patients and
therefore patients find worthy of reporting [13]. The pub-
lished consumer studies which all were conducted on na-
tional datasets showed that consumers are willing to report
many ADRs for nervous system medications, but we
do not know to which extent the above findings are
generaliserable to populations in other countries. Since
2012, researchers were allowed access to ADR data in
the EU ADR database, EudraVigilance (EV) and this has
opened for cross-national analysis based on a standardised
reporting format [14]. The objective of this study was to in-
vestigate ADR reports submitted by consumers for nervous
system medications in Europe during the first 5 years of
electronic reporting to the EVADR database.
Methods
Setting
EudraVigilance (EV) is the central database of reports of
suspected spontaneous ADR reports and ADRs reported
in clinical trials for all medicinal products authorized in
the European Economic Area (EEA) [15]. In compliance
with the EU pharmacovigilance legislation, ADRs are
reported to EV by regulatory agencies in member states
where the ADR occurred. EV was set up in December
2001 to facilitate the electronic reporting of ADRs in the
EEA. Data should be transmitted in accordance with the
ICH E2B (R2) standard [15]. The minimum information
required for an ADR report to enter the EV database is the
following parameters: type of reporter, patient, at least one
suspected active substance/medicinal product, and at least
one suspected ADR (Volume 9A) [15]. The EV database is
not publically accessible, and authorisation for data accesswas given by the European Medicines Agency. By 2012,
consumer reporting was officially accepted in 5 European
countries: Denmark, the Netherlands, Norway, Sweden
and the United Kingdom [1]. Before July 2012, countries
were only requested to forward serious consumer ADR re-
ports to the EV database [16].
Study design
The study comprised all ADR reports occurring from
2007 to 2011, located in the EV database and reported
by consumers for nervous system medications (ATC
group N). The content of the reports was analysed with
respect to seriousness, categories of ADRs classified by sys-
tem organ class (SOC) and medications. The unit of ana-
lysis was one ADR. Patients’ age was dichotomized into
two groups: children (0-17-year-olds) and adults (18 +).
Material
ADR information was provided for this study in anonym-
ous form with encrypted identification [8]. Data extraction
and data analyses of the raw material were comprehensive
and time-consuming. Information was extracted from the
ADR database on the date reports were received; category
of persons submitting the reports; and criteria of serious-
ness and medications for which the ADRs were reported.
The reported ADRs were coded according to type and ser-
iousness using CIOMS (Council for International Organi-
zations of Medical Sciences) criteria by academic staff in
the national regulatory agencies [16]. ADR data was placed
at the disposal of this study in anonymous form with
encrypted identification of the medicine user. Data were
extracted from the EV database in Microsoft Excel files
using the following criteria: patient’s sex and age, medicines
(active substance), adverse drug reaction and severity.
EMA has to ensure that, in complying with regulation
(EC) 1049/2001, the protection of privacy and integrity of
individuals is guaranteed, and therefore individual country
specific ADR information was not disclosed [17]. The
material comprised all ADRs reports from consumers
reported to the EV database from 2007 to 2011. Data
were extracted from the EV database and delivered to
us as several large Excel files. Data comprised all ADR
reports form consumers located in the EV database by
14 March 2012. In STATA® (statistical software pack-
age) the Excel files were merged into one major file
and the ADR reports were searched for duplicates.
Data analysis including coding of ADR reports was
conducted in an Access database. Each ADR report
may refer to one or more suspected ADR (s) as well as to
one or more medicinal products. In this study we included
ADRs reported for medications, which were listed as sus-
pect drug by the reporter, meaning that the reporter
suspected this drug and not the concomitant medicine to
have caused the ADR.
Table 1 Fatal consumer cases reported for nervous systems medications in Europe, 2007 to 2011
Case no. Medicine (s) ATC group Adverse drug reaction (s) Sex (M/F) Age
1 Diamorphine N02AA09 Sudden death F 18+
2 Metamizole N02BB02 Agranulocytosis F 18+
Leukopenia
Multi-organ failure
Sepsis/septic shock
3 Morphine N02AA01 Cerebrovascular accident F 18+
4 Oxycodone N02AA05 Intentional overdose/suicidal ideation M 18+
5 Apomorphine N04BC07 Pneumonia M NA
6 Apomorphine N04BC07 Intestinal haemorrhage M NA
Pneumonia aspiration
7 Apomorphine N04BC07 Anaemia F 18+
Haematocrit decreased
Red blood cell sedimentation rate increased
8 Apomorphine N04BC07 Death F NA
9 Apomorphine N04BC07 Death F 18+
10 Apomorphine N04BC07 Death F NA
11 Apomorphine N04BC07 Death F 18+
12 Carbidopa/levodopa N04BA02 Death M 18+
Entacapone, Rotigotine
13 Clomethiazole N05CM02 Leucocytosis F NA
Pyrexia
Musculoskeletal stiffness
Neuroleptic malignant syndrome
14 Clozapine N05AH02 Cardiac failure F 18+
Somnolence
15 Citalopram N06AB04 Fatigue/malaise F NA
16 Duloxetine N06AX21 Deafness F 18+
Abasia
Urinary tract infection
Septic shock
Urosepsis
Hyponatraemia
Neoplasm malignant
Aphasia
Urinary incontinence
Renal failure
17 Trimipramine N06AA06 Asthenia M 18+
Depressed level of consciousness/sedation
Tachyphrenia
Completed suicide
Dependence
Indifference
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Table 1 Fatal consumer cases reported for nervous systems medications in Europe, 2007 to 2011 (Continued)
18 Amitriptyline N06AA09 Toxicity to various agents M NA
19 Rivastigmine N06DA03 Lung infection F 18+
Mood altered/aggression
M: male, F: female, NA:no information available.
Table 2 Number of consumer adverse drug reactions for
nervous system medications in Europe by type and
seriousness, 2007 to 2011
System organ class (descending order) Number (serious)
Psychiatric disorders 868(547)
Nervous system disorders 847(424)
General disorders and administration site conditions 736(303)
Gastrointestinal disorders 651(199)
Investigations 251(151)
Skin and subcutaneous tissue disorders 236(118)
Musculoskeletal and connective tissue disorders 219(96)
Injury, poisoning and procedural complications 145(93)
Eye disorders 142(65)
Respiratory, thoracic and mediastinal disorders 123(69)
Cardiac disorders 79(57)
Vascular disorders 74(58)
Metabolism and nutrition disorders 69(44)
Renal and urinary disorders 60(38)
Ear and labyrinth disorder 56(29)
Infections and infestations 50(29)
Reproductive system and breast disorders 44(15)
Blood and lymphatic system disorders 21(21)
Social circumstances 19(14)
Surgical and medical procedures 18(17)
Hepatobiliary disorders 17(15)
Immune system disorders 16(10)
Neoplasm benign, malignant and unspecified 10(10)
Endocrine disorders 9(9)
Congenital, familial and genetic disorders 2(2)
Pregnancy, puerperium and perinatal conditions 2(2)
Total 4766 (2433)
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The different types of reported ADRs were classified
according to the Medical Dictionary for Regulatory Activ-
ities (MedDRA) System Organ Class (SOC) [18]. Serious
ADRs were defined as: fatal, life-threatening, requiring
hospitalisation or prolongation of existing hospitalisation,
resulting in persistent or significant disability/incapacity in
the reporter’s assessment, in a congenital anomaly/birth
defect and other medically important conditions. All other
ADRs are classified as non-serious [18].
Classification of medications by anatomical therapeutic
chemical (ATC) group
The ATC system is a system for classifying medicinal prod-
ucts according to their primary constituent, the organ or
system on which they act and their chemical, pharmaco-
logical and therapeutic properties [19]. Medicinal products
are classified at five different levels. The medicines are
divided into 14 main groups (first level), with one pharma-
cological/therapeutic subgroup (second level), and the fifth
level is the chemical substance [18]. As the ADR data pro-
vided by EMA did not contain any information about ATC
codes, these were added manually to the data file. The me-
dicinal products reported are referenced based on their
active substance and in this article we present ADR data at
ATC level 1 and 5 [19].
Results
From 2007 to 2011, a total of 7434 consumer ADR reports
containing information about 35349 ADRs was located in
EV. Of these, 4766 ADRs were submitted for nervous sys-
tem medications. In total, 51% of ADRs were classified as
serious and of these 19 fatal cases were reported. The char-
acteristics of the fatal cases are displayed in Table 1. The
largest number of fatal cases (n = 8) was reported for apo-
morphine (ATC group N04) followed by five fatal cases
reported for antidepressants (ATC group N06). Totally,
58% of ADRs were reported for women and 42% for men.
Less than 5% of ADRs were reported in children.
ADRs by type and seriousness
Table 2 shows the distribution of reported ADRs by
SOC. In total, consumers reported 26 ADR categories.
The largest shares of ADRs were reported for the SOCs:
nervous system disorders (18% of total ADRs), psychi-
atric disorders (18% of total ADRs); and general disorders
and administration site conditions (15% of total ADRs).The largest share of serious ADRs was of the type psychi-
atric disorders (23% of serious) followed by nervous system
disorders (17% of serious) and ADRs of the general type
(12% of ADRs).
ADRs by therapeutic groups
Table 3 displays the number of ADRs reported by
consumers distributed on therapeutic groups and ser-
iousness. Reports encompassed medicines from the thera-
peutic groups: antiepileptics (ATC group N03) (36%),
Table 3 Consumer adverse drug reactions (N) for nervous
system medications in Europe by therapeutic group and
seriousness (in parentheses), 2007 to 2011
Therapeutic group (ATC level 2) Substance Total (serious)
Anaesthetics (N01) Articaine 1(1)
Bupivacaine 4(4)
Fentanyl 24(24)
Propofol 2(2)
Sevoflurane 2(2)
Sufentanil 4(4)
Total N01 37(37)
Analgesics (N02) Buprenorphine 24(24)
Codeine 14(14)
Diamorphine 3(3)
Dihydroergotamine 27(27)
Ergotamine 2(2)
Flupirtine 6(6)
Frovatriptan 2(2)
Hydromorphone 22(22)
Metamizole 20(20)
Methylergometrine 2(2)
Methysergide 25(25)
Morphine 6(6)
Oxycodone 56(56)
Paracetamol 42(42)
Phenazone 8(8)
Pizotifen 2(2)
Propyphenazone 7(7)
Sumatriptan 3(3)
Tilidine 11(10)
Tramadol 62(57)
Total N02 344(338)
Antiepileptic drugs (N03) Carbamazepine 142(142)
Clonazepam 13(13)
Gabapentin 53(53)
Lamotrigine 78(78)
Levetiracetam 2(2)
Oxcarbazepine 36(36)
Phenytoin 6(6)
Phenobarbital 4(4)
Pregabalin 1510(1510)
Topiramate 6(6)
Valproate 17(17)
Zonisamide 3(3)
Total N03 1870(1870)
Antiparkinson drugs (N04) Amantadine 9(9)
Table 3 Consumer adverse drug reactions (N) for nervous
system medications in Europe by therapeutic group and
seriousness (in parentheses), 2007 to 2011 (Continued)
Apomorphine 45(45)
Benserazide 1(1)
Bromocriptine 26(26)
Cabergoline 1(1)
Carbidopa 43(43)
Entacapone 39(39)
Levodopa 44(44)
Piribedil 1(1)
Pramipexole 17(17)
Procyclidine 7(7)
Rasagiline 15(15)
Rotigotine 1(1)
Ropinirole 15(15)
Total N04 264(264)
Antipsychotics (N05A) Amisulpride 1(1)
Aripiprazole 19(19)
Bromperidol 8(8)
Chlorpromazine 7(7)
Chlorprothixene 23(23)
Clozapine 71(71)
Flupentixol 1(1)
Fluspirilene 2(2)
Haloperidol 12(12)
Levomepromazine 9(9)
Lithium 18(18)
Melperone 7(7)
Olanzapine 23(23)
Perphenazine 12(12)
Pipamperone 3(3)
Quetiapine 46(46)
Risperidone 37(37)
Sulpiride 7(7)
Thioridazine 6(6)
Tiapride 6(6)
Zuclopenthixol 21(21)
Total N05A 339(339)
Anxiolytics (N05B) Alprazolam 17(17)
Bromazepam 14(14)
Chlordiazepoxide 2(2)
Clorazepate 9(9)
Diazepam 19(19)
Lorazepam 74(74)
Oxazepam 8(8)
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Table 3 Consumer adverse drug reactions (N) for nervous
system medications in Europe by therapeutic group and
seriousness (in parentheses), 2007 to 2011 (Continued)
Total N05B 143(143)
Hypnotics and sedatives (N05C) Butalbital 5(5)
Clomethiazole 5(5)
Flunitrazepam 1(1)
Melatonin 4(4)
Zaleplon 3(3)
Zolpidem 14(14)
Zopiclone 12(12)
Total N05C 44(44)
Antidepressants (N06A) Agomelatine 29(29)
Amitriptyline 11(11)
Bupropion 7(7)
Citalopram 38(38)
Clomipramine 5(5)
Duloxetine 27(27)
Doxepin 1(1)
Escitalopram 25(25)
Fluoxetine 14(14)
Imipramine 1(1)
Mirtazapine 18(18)
Nortriptyline 6(6)
Opipramol 28(28)
Paroxetine 21(21)
Sertraline 22(22)
Trimipramine 7(7)
Venlafaxine 217(177)
Total N06A 477(437)
Psychostimulants (N06B) Caffeine 16(16)
Methylphenidate 61(61)
Total N06B 77(77)
Anti-dementia drugs (N06D) Memantine 2(2)
Rivastigmine 50(50)
Total N06D 52(52)
Parasympathomimetics (N07) Disulfiram 11(11)
Methylnaltrexone 2(2)
Nicotine 91(91)
Varenicline 1017(135)
Total N07 1121(239)
Total ATC group N 4766(2433)
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depressants ATC group N06A (9%). Except from parasym-
pathomimetics, the majority of ADRs were serious. In
particular, a large number of ADRs were reported forprebagalin (n = 1510) and varenicline (n = 1017). The most
commonly reported ADRs for venlafaxine were anxiety,
restlessness, paraesthesia and sleep disorder. Table 4
displays characteristics of serious ADRs reported for
pregabaline. In total, 50 ADR categories were reported; the
most frequently reported ADRs were drug ineffective/drug
effect decreased (n = 83), dizziness (n = 78), pain (n = 61),
somnolence (n = 56) and fatigue (n = 54). Table 5 dis-
plays the characteristics of serious ADRs reported for
varenicline. The largest number of reported ADRs was
musculoskeletal pain (n = 9), sleep disorder (n = 7),
chest disorder/pain (n = 7), depression (n = 6) and sui-
cidal behavior/ideation (n = 6).
Discussion
This is the first study to systematically analyse ADRs for
nervous system medications reported by consumers to
the EV database. Almost all ADRs, except for those
reported for parasympathomimetics, were serious and
several fatal cases were reported. Reported ADRs were
predominantly of the type nervous and psychiatric disor-
ders and general disorders. The majority of ADRs were
reported for pregabalin, varenicline and venlafaxine.
ADRs by type and seriousness
The most frequently reported ADRs for nervous system
medications were of the type nervous and psychiatric
disorders and this finding was expected due to the
mechanism of action of the reported nervous system
medications. Additionally, a large number of ADRs of
the type general disorders and administration site condi-
tions and gastrointestinal disorders were reported, and
this finding was also in line with results in previous con-
sumer studies [5-13]. More than one half of reported
ADRs were serious, however this reporting pattern was
not surprising, since countries were not requested to re-
port non-serious ADRs to the EV database during the
study period [16].
ADRs by therapeutic groups
The largest number of ADRs was reported for antiepi-
leptics and antidepressants, which can be explained by
the frequent use of these medications in adults [20]. A
high number of ADRs were reported for varenicline but
only few were serious. In 2007, based on consumer re-
ports in the USA, there was a high media attention on
the increased risk of serious ADRs such as suicidal idea-
tion and occasional suicidal behaviour, erratic behaviour
and drowsiness reported for varenicline leading to black
box warnings in the USA (July 2009) [21]. The ADR sig-
nal was later confirmed in a meta-analysis [22]. The high
number of ADRs reported for varenicline by European
consumers could have been stimulated by this media at-
tention; however, the majority of reported ADRs were
Table 4 Serious adverse drug reactions reported for
pregabalin by European consumers, 2007 to 2011
Adverse drug reaction(s) N
Drug ineffective/drug effect decreased 83
Dizziness 78
Pain 61
Somnolence 56
Fatigue 54
Weight changes 47
Abdominal pain 39
Nausea 36
Headache 35
Vision blurred 28
Insomnia 24
Muscle spasms 24
Oedema 24
Gait disturbance 23
Myalgia 21
Hyperhidrosis 20
Appetite changes 18
Dry mouth 18
Malaise 17
Pruritus 17
Constipation 16
Disturbance in attention 16
Depression 15
Rash 15
Balance disorder 14
Memory impairment 14
Paraesthesia 14
Vertigo 14
Withdrawal syndrome 14
Accidental exposure 13
Diarrhoea 13
Feeling abnormal 13
Speech disorder 13
Anxiety 12
Arthralgia 12
Feeling drunk 12
Tremor 12
Eye swelling 11
Nasal congestion 11
Burning sensation 10
Erectile dysfunction 10
Urinary tract disorder 10
Table 4 Serious adverse drug reactions reported for
pregabalin by European consumers, 2007 to 2011
(Continued)
Vomiting 10
Others (n < 10) 492
Total 1510
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“drug ineffective/drug effect decreased” were reported,
probably because this side effect can easily be assessed,
and is very obvious compared to many other types of
ADRs. To evaluate whether ADRs reported for pregabalin
and varenicline can act as early warning for new ADR
signals more in-depth analysis of the ADR reports should
be conducted.
Strengths and limitations of this study
The strength of this study is that data comprised all
ADRs reported by consumers in Europe, which wereTable 5 Serious adverse drug reactions reported for
varenicline by European consumers, 2007 to 2011
Adverse drug reaction(s) N
Musculoskeletal pain 9
Sleep disorder 7
Chest discomfort/pain 7
Depression 6
Suicidal behaviour/ideation 6
Nausea 5
Rash 4
Aggression 3
Mood altered/mood swings 3
Feeling abnormal 3
Headache 3
Oropharyngeal blistering/pain 3
Anxiety 2
Hallucination 2
Tearfulness 2
Fatigue 2
Pyrexia 2
Epilepsy 2
Movement disorder 2
Muscle spasms/weakness 2
Abdominal discomfort/pain 2
Erythema 2
Hypersensitivity 2
Others (n < 2) 53
Total 135
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and present in the database by March 2012. A major
limitation to this study is that we do not know to which
extent the causality of these ADRs can be confirmed,
and this has implications for the interpretation of the
findings [2]. The value of consumer reports in detection
of new ADR signals remains unclarified due to the lack
of information about causality. In this study, we did not
evaluate the validity of the consumer reports since we
only had access to the data entered into the EV database
and not the original reports. Spontaneous reporting sys-
tems suffer from various barriers, such as incomplete
recognition of ADRs, administrative barriers to reporting
and low data quality, all of which may result in under-
reporting of important serious and rare events [2]. ADRs
that are non-serious or already known may be over-
reported; however, this study provides information on
reported ADRs, and this information contributes to
broadening the knowledge on medicine safety. Before
July 2012 countries were only obliged to report ser-
ious consumer reports to EV, which may explain the
large number of serious ADRs found, and the low number
of non-serious consumer reports. Therefore there may be
additional non-serious consumer ADR reports present in
the regulatory agencies. With the new pharmacovigilance
regulation that came into force in July 2012 the share of
serious consumer reports in EV will probably decline al-
though the total number of consumer reports is expected
to increase.
Hence, it is not possible to generalize from data
reported to the EV database to the other EU member
states. Spontaneous reports are an important source of
information about new and previously unrecognized
ADRs, and the value of spontaneous reporting schemes
lies in their ability to act as hypothesis-generating proce-
dures [2]. Therefore, EMA should continue to systemat-
ically survey and analyse ADRs reported by consumers
in order to signal previously unknown ADRs. Another
important issue to be investigated in future studies is to
which extent individuals suffering from ADRs later re-
cover from the reported reactions.
Conclusion
The majority of ADRs from nervous system mediations
reported by consumers that were identified from the
EudraVigilance database were serious. The value of
consumer reports in pharmacovigilance still remains
unclarified.
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